Tumor-derived CCL2 inhibits the efficacy of ablative radiotherapy and FOLFIRINOX chemotherapy in mice, while selective blockade of CCL2 using neutralizing antibodies blocked macrophage recruitment and restored the sensitivity of PDAC tumors to radiotherapy and chemotherapy [18,19]. The gene discussed is CCL2; the disease is neoplasm.